Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
Phase Ib Trial of ABBV-637 or ABBV-155 in Combination With ERAS-801 for Glioblastoma With Amplification of the Epidermal Growth Factor Receptor
Memorial Sloan Kettering Cancer Center
60 participants
Apr 7, 2025
INTERVENTIONAL
Conditions
Summary
The researchers are doing this study to find out whether the drugs ABBV-637 and ABBV-155 are safe treatments that cause few or mild side effects when given alone or in combination with ERAS-801 in people with recurrent GBM.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
will be administered orally at the assigned dose once daily starting on Cycle 1 Day 1.
will be administered intravenously over one hour (+/- 10 min) once every 28 days on the first day of the new cycle.
will be administered intravenously over at least 30 minutes once every 21 days on the first day of the new cycle.
Temozolomide will be continued for 6 cycles after radiation.
will be given as per standard of care radiation for GBM
Locations(10)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06934889